Innovations in Oncology: Gynecologic Cancers

Are you up to date on the key clinical data for available immuno-oncologic agents in advanced endometrial and cervical cancers?

This educational series examines the significance and potential impact of immunotherapy and antibody-drug conjugates in patients with advanced endometrial and cervical cancers. Our global experts discuss key clinical data from first- and second-line treatment, management considerations during immuno-oncologic therapy, and more!

Provided by:

In Partnership with:

LikeLikedUnlike

Episodes 1-2 of 2

- Robert L. Coleman, MD, FACOG, FACS
  Peer
- Susana Campos, MD, MPH
  Peer
- Domenica Lorusso, MD, PhD
  Peer
1
CME/CE
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
0.50 credits
- Robert L. Coleman, MD, FACOG, FACS
  Peer
- Susana Campos, MD, MPH
  Peer
- Ana Oaknin, MD, PhD
  Peer
1
CME/CE
Establishing the Role of Immunotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Endometrial Cancer
Establishing the Role of Immunotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Endometrial Cancer
0.50 credits